Oncopeptides AB (publ) (ONCO.ST)
SEK 2.01
(2.87%)
SEK 2.01
(2.87%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -66.92 Million SEK | 80.02% |
| 2022 | -334.97 Million SEK | 3.74% |
| 2021 | -347.99 Million SEK | 57.61% |
| 2020 | -820.9 Million SEK | 10.73% |
| 2019 | -919.53 Million SEK | -144.81% |
| 2018 | -375.61 Million SEK | 7.04% |
| 2017 | -404.05 Million SEK | -903.83% |
| 2016 | -40.25 Million SEK | -1655.38% |
| 2015 | -2.29 Million SEK | 80.84% |
| 2014 | -11.96 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -268.38 Million SEK | -3142.95% |
| 2024 Q1 | 8.82 Million SEK | 113.18% |
| 2023 Q2 | -53.93 Million SEK | 68.64% |
| 2023 Q3 | -53.16 Million SEK | 1.43% |
| 2023 Q4 | -66.92 Million SEK | -25.88% |
| 2023 Q1 | -171.95 Million SEK | 48.66% |
| 2023 FY | -66.92 Million SEK | 80.02% |
| 2022 Q3 | -421.5 Million SEK | -399.83% |
| 2022 Q1 | -187.96 Million SEK | 45.99% |
| 2022 Q2 | -84.32 Million SEK | 55.14% |
| 2022 FY | -334.97 Million SEK | 3.74% |
| 2022 Q4 | -334.97 Million SEK | 20.53% |
| 2021 FY | -347.99 Million SEK | 57.61% |
| 2021 Q4 | -347.99 Million SEK | 48.14% |
| 2021 Q3 | -671.07 Million SEK | 32.77% |
| 2021 Q2 | -998.11 Million SEK | -170.58% |
| 2021 Q1 | -368.88 Million SEK | 55.06% |
| 2020 Q2 | -924.99 Million SEK | -52.52% |
| 2020 Q4 | -820.9 Million SEK | 33.89% |
| 2020 Q3 | -1.24 Billion SEK | -34.24% |
| 2020 Q1 | -606.46 Million SEK | 34.05% |
| 2020 FY | -820.9 Million SEK | 10.73% |
| 2019 Q1 | -742.38 Million SEK | -97.65% |
| 2019 Q3 | -1.11 Billion SEK | -79.73% |
| 2019 Q4 | -919.53 Million SEK | 17.84% |
| 2019 FY | -919.53 Million SEK | -144.81% |
| 2019 Q2 | -622.69 Million SEK | 16.12% |
| 2018 Q1 | -664.94 Million SEK | -64.57% |
| 2018 Q3 | -488.86 Million SEK | 13.96% |
| 2018 FY | -375.61 Million SEK | 7.04% |
| 2018 Q4 | -375.61 Million SEK | 23.17% |
| 2018 Q2 | -568.21 Million SEK | 14.55% |
| 2017 Q1 | -611.59 Million SEK | -1419.47% |
| 2017 Q4 | -404.05 Million SEK | 8.78% |
| 2017 Q3 | -442.96 Million SEK | 17.21% |
| 2017 Q2 | -535.06 Million SEK | 12.51% |
| 2017 FY | -404.05 Million SEK | -903.83% |
| 2016 Q4 | -40.25 Million SEK | 0.0% |
| 2016 FY | -40.25 Million SEK | -1655.38% |
| 2016 Q1 | 2.29 Million SEK | 0.0% |
| 2015 FY | -2.29 Million SEK | 80.84% |
| 2014 FY | -11.96 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alzinova AB (publ) | -21.22 Million SEK | -215.274% |
| Amniotics AB (publ) | -5.63 Million SEK | -1088.21% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -2996.714% |
| BioArctic AB (publ) | -606.58 Million SEK | 88.968% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1339.259% |
| Camurus AB (publ) | -1.16 Billion SEK | 94.257% |
| Cantargia AB (publ) | -139.74 Million SEK | 52.113% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -7150.271% |
| Genovis AB (publ.) | -43.94 Million SEK | -52.295% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 20.087% |
| Mendus AB (publ) | -96.29 Million SEK | 30.504% |
| Kancera AB (publ) | -45.69 Million SEK | -46.459% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 18.591% |
| LIDDS AB (publ) | -13.51 Million SEK | -395.263% |
| Lipum AB (publ) | -8.46 Million SEK | -690.549% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -109.603% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 225.735% |
| NextCell Pharma AB | -46.79 Million SEK | -43.02% |
| OncoZenge AB (publ) | -12.62 Million SEK | -429.975% |
| Saniona AB (publ) | 40.44 Million SEK | 265.451% |
| Simris Alg AB (publ) | 85.07 Million SEK | 178.66% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 79.941% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 140.295% |
| Xintela AB (publ) | -7.8 Million SEK | -756.96% |
| Ziccum AB (publ) | -2.13 Million SEK | -3031.493% |
| AcouSort AB (publ) | -23.98 Million SEK | -178.996% |
| Active Biotech AB (publ) | -33.2 Million SEK | -101.566% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -127.751% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -251.102% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 51.559% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 48.322% |
| CombiGene AB (publ) | -101.44 Million SEK | 34.03% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 18.476% |
| Intervacc AB (publ) | -88.16 Million SEK | 24.093% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -33.784% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -34.017% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 426.28% |
| Corline Biomedical AB | -17.01 Million SEK | -293.369% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 20.089% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -69.925% |
| Aptahem AB (publ) | 2.9 Million SEK | 2400.73% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 79.664% |
| Fluicell AB (publ) | -2.76 Million SEK | -2322.005% |
| Biovica International AB (publ) | -58.73 Million SEK | -13.932% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -47.997% |
| Abliva AB (publ) | -57.24 Million SEK | -16.911% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 65.629% |
| 2cureX AB (publ) | -13.4 Million SEK | -399.291% |
| I-Tech AB | -83.26 Million SEK | 19.627% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 149.678% |
| Cyxone AB (publ) | -16.67 Million SEK | -301.44% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -19.744% |
| Biosergen AB | -1.88 Million SEK | -3453.903% |
| Nanologica AB (publ) | -9.38 Million SEK | -612.825% |
| SynAct Pharma AB | -61.75 Million SEK | -8.358% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -212.491% |
| BioInvent International AB (publ) | -236.3 Million SEK | 71.681% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -405.851% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -1191.662% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -221.839% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -2151.682% |